High-Risk Human Papillomavirus Detection in Urine Samples From a Referral Population With Cervical Biopsy-Proven High-Grade Lesions
Nenhuma Miniatura disponível
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
LORENZI, Adriana T.
FREGNANI, Jose Humberto T.
DOCKTER, Janel
FITZGERALD, Kerry
STROHECKER, Elizabeth
EATON, Barbara
VIBAT, Cecile Rose T.
ERLANDER, Mark G.
SCAPULATEMPO-NETO, Cristovam
SMITH, Jennifer S.
Citação
JOURNAL OF LOWER GENITAL TRACT DISEASE, v.22, n.1, p.17-20, 2018
Resumo
Objective: The aim of the study was to evaluate the performance of the HPV-HR test to detect high-risk human papillomavirus (HPV) in urine samples in comparison with a commercial molecular HPV test. Materials and Methods: This is a prospective study, in which 350 patients diagnosed previously with cervical intraepithelial neoplasia (CIN) grade 2 or higher were enrolled. Urine and cervical specimens were collected. Urine was tested with the HPV-HR test and cervical specimens were tested with the Cobas. Results: Of the 336 evaluable patients, there were 271 cases of CIN 2+, of which 202 were CIN 3+ and the remaining 65 patients were less than CIN 2. Positivity was 77.1% (95% confidence interval [CI] = 72.5-81.5) for the urine samples and 83.6% (95% CI = 79.6-87.6) for the cervical samples. Agreement between cervical and urine samples for HPV detection was 79.8% ( = 0.363; 95% CI = 0.243-0.484). Sensitivity for CIN 2+ was 83.4% (95% CI = 78.4-87.6) for urine and 90.8% (95% CI = 86.7-92.9) for cervical samples. The sensitivity for CIN 3+ was 85.6% (95% CI = 80.0-90.2) for urine and 92.6% (95% CI = 88.0-95.8) for cervical samples. Specificity for worse than CIN 2 was 50.8% (95% CI = 33.7-59.0) and 46.2% (95% CI = 33.7-59.0) for urine and cervical samples, respectively. Conclusions: Although these results demonstrated slightly higher detection rates for HR-HPV and clinical sensitivity in cervical samples than in urine, when compared with histological diagnoses, urine sampling is a viable alternative to access women who do not participate in routine screening programs.
Palavras-chave
HPV, cervical cancer, screening, trovagene, urine
Referências
- Arbyn M, 2015, CANCER EPIDEM BIOMAR, V24, P769, DOI 10.1158/1055-9965.EPI-14-1417
- Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9
- Cuzick J, 2015, PERFORMANCE TROVAGEN
- Goodman A, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2372
- Kurman RJ, 2014, WHO CLASSIFICATION T
- Lorenzi AT, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0342-0
- Lorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092
- Mauad EC, 2009, RURAL REMOTE HEALTH, V9
- Pathak N, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5264
- Richardson LA, 2015, CANCER CYTOPATHOL, V123, P745, DOI 10.1002/cncy.21596
- Sahasrabuddhe VV, 2014, J CLIN VIROL, V60, P414, DOI 10.1016/j.jcv.2014.04.016
- Senkomago V, 2016, J CLIN VIROL, V74, P26, DOI 10.1016/j.jcv.2015.11.005
- Stanczuk G, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010660
- Vorsters A, 2012, EUR J CLIN MICROBIOL, V31, P627, DOI 10.1007/s10096-011-1358-z